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INTRODUCTION
Hyperglycemia can worsen a number of periopera-
tive problems, including cardiac, neurologic, and in-
fectious complications (1). Hyperglycemia occurs
frequently in patients with and without diabetes dur-
ing cardiovascular surgery, especially during cardio-
pulmonary bypass. In a study by Van den Berghe
and colleagues (2), intensive insulin therapy after
surgery reduced morbidity and mortality in criti-
cally ill patients, most of whom underwent cardiac
surgery. High-risk cardiac patients were found to
derive the greatest benefit from intensive insulin
therapy. However, strict glucose control is difficult
to achieve during cardiovascular procedures requir-
ing cardiopulmonary bypass because of the stress
of surgery, including anesthesia, cardioplegia, and
inotropic support (3-5). Optimal glucose control is
unlikely when glucose concentrations are measured
only episodically.
In the first half of this review, we will present
problems associated with glucose toxicity, role of in-
sulin, and literature review of large randomized stud-
ies regarding intensive insulin therapy in the field
of cardiovascular surgery. In the latter half, our clini-
cal trial to evaluate the efficacy of the artificial endo-
crine pancreas during cardiovascular surgery will
be presented and discussed.
GLUCOSE TOXICITY AND THE ROLE OF
INSULIN
Glucose Toxicity
Glucose toxicity, in its narrow sense, refers to a
clinical condition where control of diabetes is par-
ticularly poor, since hyperglycemia itself reduces
the insulin secretion capacity of pancreatic β -cells,
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and the induced insulin resistance leads to further
hyperglycemia. This vicious circle finally leads to the
total incapacity of β -cells to secrete insulin (6, 7).
On the other hand, glucose toxicity in its wide sense
refers to various complications due to diabetes. As
for the cytotoxic mechanism due to hyperglycemia,
the four contributing metabolic pathways are known
as :
1. The polyol pathway
2. The hexosamine pathway
3. The advanced glycosylation end product (AGE)-
producing pathway and
4. The diacyl glycerol (DAG)-producing pathway.
Recent fundamental research findings suggest
that oxidative stress greatly influences the molecu-
lar mechanism of the reduction of insulin biosyn-
thesis and secretion, which constitutes the main eti-
ology of this glucose toxicity (1). Figure 1 shows
the mechanism for the increase of oxidative stress
in diabetes. There are two pathways known as the
glycation reaction and the mitochondreal electron
transfer system. In the glycation reaction, a Shiff
base is formed of glucose and protein followed by
an Amadoric compound, after which AGE and reac-
tive oxygen species (ROS) are produced as metabo-
lites, leading to an increase in oxidative stress (8).
In the mitochondreal electron transfer system, ATP
and ROS are produced through the TCA cycle,
which also leads to oxidative stress increase. Figure
2 illustrates the molecular mechanism of the reduc-
tion in insulin secretion caused by the increase in
oxidative stress. When ROS increases due to chronic
hyperglycemia, and oxidative stress increases, PDX-
1 (pancreatic duodenal homeobox-1) activity de-
creases in pancreatic β -cells, and, as a result, glu-
cokinase activity and insulin biosynthesis decrease,
followed by a decrease in insulin secretion. MafA
is a recently isolated β -cell specific transcription
factor which functions as a potent activator of insu-
lin gene transcription. It was shown recently that
Figure 1. Increase in oxidative stress in the diabetic state
Acceleration of glycation response and the intramitochondrial electron transfer system was detected in the diabetic state, causing
oxidative stress as the responses accelerate. AGE : advanced glycosylation end products ; ROS : reactive oxygen species ; TCA cy-
cle : tricarboxilic acid cycle ; ATP : adenosine tri -phosphate
Figure 2. The mechanism of insulin secretion reduction due to glucose toxicity
DNA binding activities of PDX-1 and MafA decrease as a result of oxidative stress caused by hyperglycemia, while insulin biosyn-
thesis and secretion also decrease. ROS : reactive oxygen species ; PDX-1 : pancreatic duodenal homeobox-1
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expression and/or DNA binding activities of MafA,
together with PDX-1, are reduced after chronic
exposure to a high glucose concentration (9).
Diabetic complications
These mechanisms cause complications in dia-
betes, which are divided into chronic and acute com-
plications based on the disease course (Table 1).
Chronic complications are further divided into mi-
crovascular diseases, which are specific, to and com-
mon in diabetes, and macrovascular diseases, which
are not specific but frequent and thus important for
prognosis. Chronic hyperglycemia can induce mi-
crovascular complications such as retinopathy, neu-
ropathy or nephropathy (10). It can also induce
macrovascular complications partially, such as aor-
tic sclerosis, stroke, myocardial infarction, angina
pectoris, and obstructive peripheral vascular disease.
Acute complications include diabetic coma and acute
infection. Especially, acute infection is the biggest
problem in surgery patients.
The two major problems associated with acute
hyperglycemia are infection and cardiovascular dis-
orders. The causes of infection are :
1. Diminished leukocyte chemotaxis,
2. Diminished granular phagocytic activity, and
3. Diminished intracellular bactericidal capacity
(11, 12).
Cardiovascular disorders, on the other hand, are
caused by :
1. Impaired myocardial protection by hyperglycemia
due to changes in cardiomyocyte cell communica-
tion
2. Diminished control function of coronary circula-
tion in the ischemic region
3. Impaired myocardial protection resulting from
ischemic preconditioning and anesthetic precondi-
tioning. Inhibition of mitochondrial KATP channel ac-
tivation is thought to be another cause of this im-
pairment (13-15).
Effects of insulin
In addition to reducing blood glucose levels, the
insulin used in intensive insulin therapy has itself
a vulnerary effect and provides myocardial protec-
tion. The basic vulnerary effects of insulin are anti-
inflammatory and antioxidant (16). In fact, it is
claimed that intensive use of insulin for an injury
can reduce mortality due to multiple organ failure
associated with sepsis. Insulin is thought to exert
its constant growth promotion and wound healing
effects because it is closely related to growth fac-
tors with vulnerary effects such as the insulin-like
growth factor (IGF) (17). Also, insulin maintains the
constant state of vascular endothelial cells through
nitric oxide (NO) synthase activation, while it also
diminishes oxidative stress and cytokine production.
On the other hand, glucose insulin (GI) and glucose
insulin potassium (GIK) therapies are representative
of the myocardial protective effect of insulin (18).
LITERATURE REVIEW OF INTENSIVE IN-
SULIN THERAPY
Effects of glucose management in ICU
Intensive insulin therapy is used for critically ill
patients, and its specific aims are multiple organ pro-
tection and the prevention and treatment of infec-
tion (2, 19-24). Intensive insulin administration nor-
malizes blood glucose levels and maintains normal
levels. Originally, the target for this method was a
blood glucose level of 80-110 mg/dl (2), but later
many modified versions were introduced that aimed
for a blood glucose level upper limit of around 140
to 180 mg/dl (22-24). The greatest reduction in
mortality resulting from this therapy involves death
due to multiple-organ failure with a proven septic
focus.
The first paper deals with the effects of glucose
Table 1 : Types of diabetic complications
Chronic complications
Microvascular diseases : retinopathy, neuropathy, nephropathy
Macrovascular diseases : aortic sclerosis, stroke, myocardial infarction, angina pectoris, obstructive peripheral vascular disease, etc.
Others : cataract, dermatopathy, hypertension, osteopenia, osteomalacia, arthropathy, soft tissue fibromatosis, etc.
Acute complications
Diabetic coma : ketoacidotic coma, non-ketotic hyperosmolar coma, lactatic acidosis
Acute infection : bacterial, mycotic, viral, etc.
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management in the intensive care unit (ICU). Van
den Berghe and co-workers (2) in Belgium pub-
lished the paper “Intensive Insulin Therapy in Criti-
cally Ill Patients” in the New England Journal of
Medicine in 2001. Patients were randomly assigned
to receive intensive insulin therapy (maintenance of
blood glucose at a level between 80 and 110 mg/dl)
or conventional treatment (infusion of insulin only
if the blood glucose level exceeded 215 mg/dl and
maintenance of glucose at a level between 180 and
200 mg/dl). With a total of 1,548 patients enrolled,
intensive insulin therapy reduced mortality during in-
tensive care from 8.0% with conventional treatment
to 4.6%. The benefit of intensive insulin therapy was
attributable to its effect on mortality among patients
who remained in ICU for more than five days (20.2%
with conventional treatment, as compared with 10.6%
with intensive insulin therapy). Figure 3 represents
Kaplan-Meier curves showing cumulative survival
of patients who received intensive insulin treatment
or conventional treatment in ICU. Figure 3A shows
the survival rate in ICU, and Figure 3B the in-hospi-
tal survival rate. Later, the same authors published
many study reports which had a major impact, so
that intensive insulin therapy rapidly found accep-
tance worldwide (19-21).
Surviving Sepsis Campaign guidelines
In association with the Surviving Sepsis Campaign
guidelines for management of severe sepsis and
septic shock were published in Critical Care Medi-
cine in 2004 (25). With these guidelines, the survival
rate improved with a blood glucose level of 80-110
mg/dl, but a target blood glucose level of 150 mg/
dl was recommended because of the risk of hypo-
glycemia. It was shown that blood glucose value
management is more important than managing the
total amount of insulin, while frequent blood glucose
measurements are essential. A revised edition of
the guidelines was published in 2008 (26), but the
recommended target blood glucose value remained
150 mg/dl or less.
Prospective randomized controlled studies of glyce-
mic control
Several large-scale multicenter studies of glyce-
mic control have been performed, and three of the
most well - known are the VISEP Trial (27), the
Glucontrol Study (28), and the NICE-SUGAR study
(29). The VISEP Trial was started as a 2-year study
of insulin therapy or other effects of severe sepsis
involving 17 German institutions. The study started
with 600 patients in 2003, but was discontinued in
2005 when the number had dropped to 537. The
reason for the dropout was frequent hypoglycemia.
The Glucontrol Multi-Center Study was a large
study, which started with 3,500 patients in 21 Euro-
pean institutions in 2004. The aim of this study was
to compare results for two groups with target blood
glucose values of 80-110 and 140-180, but this was
Figure 3. Kaplan-Meier curves showing cumulative survival of patients who received intensive insulin treatment or conventional
treatment in the intensive care unit.
(from Ref. 2 Van den Verghe G, et al. N Eng J Med 345, 1359-1367, 2001)
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also discontinued suddenly with only 1,101 cases
remaining. For this study, too, the reason for can-
cellation was a very high incidence of hypoglyce-
mia.
The results of the subsequent NICE-SUGAR
study, which compared target blood glucose values
of 81-108 and 144-180 in two groups and was per-
formed in Oceania and North America attracted the
most interest. Results were presented recently, but
were contrary to expectations. We will discuss the
details later. In a large study, we found that “tight
glycemic control with the aid of a manual easily
leads to hypoglycemia”.
Recent reports on intensive insulin therapy
Some recent negative reports about intensive in-
sulin therapy have led to a reconsideration of in-
tensive insulin therapy (29-31). One study which
used a meta-analysis to examine mortality among
critically ill patients was published in JAMA of Au-
gust, 2008 (30). No differences in in-hospital mor-
tality rates were observed between the conventional
and intensive therapy groups. Few patients in the
intensive therapy group suffered from sepsis, but
hypoglycemic incidence was very high (13.7% vs.
2.5%), thus warranting further attention.
The results of the previously mentioned NICE-
SUGAR study were presented in the March issue of
the New England Journal of Medicine (29). Contrary
to everyone’s expectations, the mortality for the
intensive therapy group after 90 days (target blood
sugar value : 81-108 mg/dl) was higher (27.5% vs
24.9%) than that for the conventional therapy group
(target blood sugar value : 144 - 180 mg/dl). Do
these findings mean that intensive insulin therapy
should be discarded entirely? Although this is prob-
ably not the case, it is clear that there is an urgent
need for the establishment of a new blood glucose
control method that does not cause hypoglycemia.
Intensive insulin therapy during cardiovascular sur-
gery
Next, we will briefly introduce the main publica-
tions on intensive insulin therapy during cardiovas-
cular surgery. In the field of cardiovascular surgery,
the importance of controlling postoperative blood
glucose values at 200 mg/dl or less has been rec-
ognized since the late 1990s (32, 33). After that,
many reports regarding usefulness of intensive insu-
lin therapy during cardiovascular surgery were pub-
lished (34-37). In a study by Van den Berghe and
colleagues, intensive insulin therapy after surgery
reduced morbidity and death in critically ill patients,
most of whom had undergone cardiac surgery.
Furnary et al. (32) reported in 1999 that sternal
infection decreased by 58% when they controlled
postoperative blood glucose values at 150-200 mg/
dl in coronary artery bypass patients. Similarly,
when they closely controlled blood glucose values
in coronary artery bypass patients from the intraop-
erative stage(before median sternotomy) for three
days postoperatively, not only sternal infection but
also mortality reportedly decreased by 57%. They
therefore emphasized the significance of glycemic
control during and after surgery (34).
As for glycemic control during cardiopulmonary
bypass, one study analyzed 1,579 adult patients with
diabetes who underwent cardiovascular surgery in
2005 (38). For patients whose blood glucose level
during cardiopulmonary bypass was more than 360
mg/dl, the mortality increased from 1.7% to 6%.
That is why hyperglycemia of more than 300 mg/
dl should be avoided, even temporarily, if the pa-
tients have diabetes. Cases with blood glucose lev-
els exceeding 300 mg/dl may be considered rare
occurrences, but as I will show later, there were a
great many cases with blood glucose levels of more
than 300 mg/dl during cardiopulmonary bypass
when we used continuous monitoring.
These background findings resulted in a review
that was published in 2006, which could be consid-
ered guidelines for cardiopulmonary bypass (39).
This review covers eight risk factors of adult car-
diopulmonary bypass as evidence for the guidelines.
In addition to neuropathy, hemodilution, and inflam-
matory reaction, glycemic control is mentioned as
very important evidence. The review emphasizes the
importance of maintaining blood glucose levels
within the normal range for all patients, includ-
ing those with no diagnosis of diabetes and those
undergoing cardiopulmonary bypass, during the en-
tire perioperative period classified as Class I, Level B.
CURRENT INTRAOPERATIVE BLOOD GLU-
COSE MANAGEMENT
Intraoperative glycemic control at Tokushima Uni-
versity Hospital
For a clear understanding of the present condi-
tions of perioperative glycemic control at our hos-
pital, here is a brief retrospective presentation of
intraoperative glycemic control policies for major
surgery and changes in real blood glucose values
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during 2007. This review covers 74 hepatectomies,
12 pancreatico duodenectomies, 24 esophagecto-
mies and 35 cardiovascular surgeries with cardio-
pulmonary bypass. Table 2 shows intraoperative
blood glucose levels and insulin consumption di-
vided into groups according to presence or absence
of diabetes and the operative method. The conven-
tional glycemic control policy resulted in target
blood glucose values maintained at around 150-
200 but frequently cases were not managed within
the target range. Especially during cardiovascular
surgery, hyperglycemic states with blood glucose
values of 400 mg/dl or more often occurred during
extracorporeal circulation, even in cases without dia-
betes, and blood glucose control was often difficult.
The next year, from January 2008, we tried inten-
sive insulin therapy for stricter glycemic control by
using manual insulin injection according to a slid-
ing scale. Table 3 shows intraoperative glycemic
control from January to the end of May 2008. Glu-
cose and insulin were administered positively and
the targeted intraoperative blood glucose value was
between 100 and 150 mg/dl. Use of insulin was
higher than in 2007, and slightly lower blood glu-
cose values were maintained, but remained unsat-
isfactory. Intraoperative glycemic control was also
difficult especially for cardiovascular surgery.
The challenge
The challenge we faced was how to achieve strict
intraoperative glycemic control without hypoglyce-
mic risk when blood glucose values vary widely.
We had to choose between two methods. One was
a stricter protocol of glycemic control. For this, we
shortened the time between blood sugar measure-
ments and made the insulin dose more precise.
However, this increased the work load of the anes-
thesiologist. The other method was to entrust the
work to a computer and a machine, which allows for
continuous blood glucose monitoring and an auto-
matic control system. We firmly opted for the sec-
ond method.
Table 2 : Intraoperative glycemic control situation of Tokushima University Hospital from January to December in 2007
(Retrospective study)
Target BS : 150-200 mg/dl
[Median (Max-Min)]
[MeanSD]
BS (mg/dl) Insulin (U)
Hepatectomies
(n=74)
DM (-) n=57
DM (+) n=17
175 (72-309)
218 (84-449)
1.53.6
9.312.5
Pancreatico duodenectomies
(n=12)
DM (-) n=7
DM (+) n=5
162 (105-270)
172 (79-261)
4.710.0
3.94.4
Esophagectomies
(n=24)
DM (-) n=22
DM (+) n=2
120 (90-165)
163 (107-210)
0
0
Cardiovascular surgeries with cardiopulmonary bypass
(n=35)
DM (-) n=29
DM (+) n=6
179 (74-454)
204 (95-361)
1.43.6
4.86.9
BS : Blood sugar, DM : Diabetes mellitus
Table 3 : Intraoperative glycemic control situation of Tokushima University Hospital from January to May in 2008
(Prospective study)
Target BS : 100-150 mg/dl
[Median (Max-Min)]
[MeanSD]
BS (mg/dl) Insulin (U)
Hepatectomies
(n=18, DM 2 cases) 174 (85-317) 2.2
4.5
Pancreatico duodenectomies
(n=6, DM 1 case) 162 (92-251) 1.7
4.1
Esophagectomies
(n=8, DM 0 case) 114 (88-160) 0
Cardiovascular surgeries with cardiopulmonary bypass
(n=11, DM 3 cases) 169 (72-341) 7.2
7.1
BS : Blood sugar, DM : Diabetes mellitus
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CONTINUOUS BLOOD GLUCOSE MONI-
TORING AND CONTROL SYSTEM
Artificial endocrine pancreas
In December 2007, our clinical team at Tokushima
University initiated a clinical trial to evaluate the
efficacy of the artificial pancreas for intra-operative
patients. Two Nikkiso STG -22 artificial pancreas
systems (Figure 4) were put into clinical use at
Tokushima University for intra- and post-operative
glucose control. In order to familiarize ourselves
with the device we first used the STG -22 only for
glucose monitoring purposes combined with insu-
lin administration according to a sliding scale, and
not for glucose control. Once the standard opera-
tional procedure was established, we used the STG-
22 for closed-loop intensive glucose control.
The STG -22 from Nikkiso in Tokyo is an origi-
nal artificial endocrine pancreas with a closed-loop
glycemic control system that provides continuous
blood glucose monitoring through a glucose sensor
electrode and automatically administers subsequent
insulin and glucose infusions to maintain appropri-
ate blood glucose levels (40, 41).
The applications for this device are :
1. Emergency treatment during hyperglycemia (that
is, diabetic coma)
2. Diagnosis of insulin resistance and the secre-
tional capacity of patients with diabetes
3. Glycemic control during surgery, trauma and
delivery (including patients without diabetes).
This device is designed to simulate the pancre-
atic function by means of mechanical engineering
(Figure 4). The glucose infusion pump is equiva-
lent to the glucagon secretion mechanism in the α -
cells of the pancreas, the glucose reservoir to the
α -granules, the glucosensor to the cell membrane,
the battery to the mitochondria, the computer to
the nucleus, the insulin reservoir to the β -granules
of the β -cells of the pancreas, an the insulin infu-
sion pump to the insulin secretion mechanism.
The artificial pancreas STG -22 is composed of
a glucose sensor, which performs glucose detection
and monitoring, and pumps for infusing the appro-
priate amount of insulin or glucose. The insulin and
glucose pumps are computer-regulated based on a
targeted blood glucose value determined before op-
eration of the system is started. It is important to
recognize that the STG -22’s glucose sensor, which
withdraws the blood from the patient at a rate of 2
ml per hour, is capable of continuously measuring
the blood glucose level with its glucose sensor, and
Figure 4. Concept of artificial endocrine pancreas
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automatically infuses insulin or glucose to adjust the
blood glucose level of the patients in accordance
with the target glucose value, which is an adapta-
tion of what we call the “closed loop system”. This
device provides continuous blood glucose monitor-
ing by means of dual lumen catheter blood sam-
pling, a high-quality roller pump and a glucose sen-
sor electrodes with glucose oxidase membrane.
The measured blood glucose level is then inputted
into a computer, and the infusion rate of insulin or
glucose is determined with an algorithm.
Accuracy of a continuous blood glucose monitoring
Yamashita et al. have published several papers
regarding the reliability and accuracy of the STG-
22 for continuous blood glucose monitoring (42,
43). Figure 5A shows data obtained during surgery,
and Figure 5B shows the data after surgery. Blood
glucose measured continuously with the STG -22
correlated strongly with measurements obtained
intermittently with a conventional laboratory glu-
cometer.
Two types of continuous glucose monitoring sys-
tems are currently in use : a continuous subcutane-
ous glucose monitor and a continuous blood glu-
cose monitor. The continuous subcutaneous glucose
monitoring system might be less invasive than a
continuous blood glucose monitoring system. How-
ever, the precision of both these types of continu-
ous glucose monitors is controversial. It has been
reported that a continuous subcutaneous glucose
monitor had a larger error (44). STG -22 is cur-
rently the only continuous blood glucose monitor-
ing device in the world, it might be a useful option
for intensive insulin therapy.
INTENSIVE INSULIN THERAPY DURING
CARDIOVASCULAR SURGERY
Continuous blood glucose monitoring during off-
pump coronary artery bypass grafts
To establish an intensive insulin therapy during
cardiovascular surgery, we first employed continu-
ous monitoring of blood glucose values while using
off-pump coronary artery bypass grafts (OPCAB)
and during cardiovascular surgery with a cardiopul-
monary bypass, and looked for any changes in in-
traoperative blood glucose values. Figure 6 shows
continuous blood glucose monitoring during OPCAB.
Effective continuous blood glucose monitoring was
possible, but in all cases few changes in intraop-
erative blood glucose levels were observed during
OPCAB surgery.
Figure 5. Accuracy of a continuous blood glucose monitoring
(A : from Ref. 42 Yamashita K, et al. Anesth Analg 106 : 160-163, 2008, B : from Ref. 43 Yamashita K, et al. Acta Anaesthsiol Scand
53 : 66-71, 2009)
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Continuous blood glucose monitoring during car-
diovascular surgery with cardiopulmonary bypass
Next, we tried continuous blood glucose moni-
toring during cardiovascular surgery with cardio-
pulmonary bypass. However, we encountered a ma-
jor problem here because not enough blood was
obtained for monitoring. This necessitated intraop-
erative suspension of continuous blood glucose
monitoring in three of the first five cases. Blood
sampling via the venous side of the cardiopulmon-
ary bypass circuit was tried in the subsequent cases,
which enabled us to obtain sufficient quantities of
blood.
Figure 7 is one typical case of continuous blood
glucose monitoring during cardiovascular surgery
with cardiopulmonary bypass. We found that sig-
nificant hyperglycemia occurred during cardiopul-
monary bypass after initiation of cardiopulmonary
bypass using an aortic clamp, the blood glucose
level increased markedly to around 300 mg/dl.
After the aortic de-clamp and termination of the
extracorporeal circulation, blood glucose showed a
tendency to decrease, but hyperglycemia of around
200 mg/dl persisted in many cases.
Why does hyperglycemia occur during cardiovas-
cular surgery (especially during cardiopulmonary
bypass) ?
One of the main reasons for the occurrence of
hyperglycemia during cardiovascular surgery (espe-
cially during cardiopulmonary bypass) is suppression
Figure 6. Continuous blood glucose monitoring during off -pump coronary artery bypass grafts
BS ; blood sugar
Figure 7. Continuous blood glucose monitoring during cardiovascular surgery with cardiopulmonary bypass
BS ; blood sugar : CPB ; cardiopulmonary bypass : AO ; Aorta
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of insulin secretion. This is caused by a reduction
in the pancreatic blood flow, the inhibition of β -cell
activity of the pancreas due to hypothermia, and
the increased secretion of insulin counter- regu-
latory hormones. Other reasons are intracellular
disorder of glucose use due to peripheral circu-
latory failure and inhibition of the glycolytic path-
way enzyme due to hypothermia.
We do not use it in this hospital, the effect of car-
dioplegia and priming solution including glucose
may be thought.
The causes of insufficiency of blood drawn dur-
ing cardiopulmonary bypass are due to hypothermia,
peripheral circulatory failure (low perfusion), vaso-
constriction and posture (especially with arms ele-
vated or bent). This problem was solved by sam-
pling blood via the venous side of the cardiopul-
monary circuit, thus rendering continuous blood glu-
cose monitoring stable and reliable even during car-
diovascular surgery with cardiopulmonary bypass.
Intensive insulin therapy during cardiovascular sur-
gery using the artificial endocrine pancreas
Figure 8 shows one case of intensive insulin ther-
apy during cardiovascular surgery using the artifi-
cial endocrine pancreas. The blood glucose level
suddenly started to increase after the initiation of
cardiopulmonary bypass, but only to a maximum of
150 mg/dl, and the level was controlled by appro-
priate insulin administration. After termination of the
cardiopulmonary bypass, the blood glucose level
began to decrease, but hypoglycemia was avoided
by means of appropriate glucose administration.
PROBLEMS AND PROSPECTS
Problems
Some of the questions associated with intensive
insulin therapy are :
What is the optimal glycemic control target?
Which patients are indicated?
In this connection, glycemic control policy may be
determined depending on patients, clinical condi-
tions, and particular operative procedures. Other
questions are :
Is the mean blood glucose value important? Is it im-
portant to reduce variability of blood glucose con-
centration (45, 46)? An artificial pancreas system,
such as the bedside-type STG -22, can help achieve
stable glucose control (47-50), but it is large and
expensive, difficult to operate, and can be used for
only a short period of time.
Merits and demerits of the representative periopera-
tive blood glucose management procedures
The merits of the conventional sliding scale
method are few hypoglycemic attacks, a small work
load because of few blood glucose measurements,
and low cost. On the other hand, a disadvantage is
that close glycemic control is difficult. An advan-
tage of open-loop intensive insulin therapy is that
it allows for close glycemic control, but drawbacks
are the possibility of hypoglycemic attack, a heav-
ier work load due to frequent blood glucose meas-
urements, and an increase in incident development.
The merits of closed-loop intensive insulin ther-
apy using the artificial endocrine pancreas are that
Figure 8. Intensive insulin therapy during cardiovascular surgery using the artificial endocrine pancreas
BS ; blood sugar : CPB ; cardiopulmonary bypass : GIR ; glucose infusion rate : IIR ; insulin infusion rate
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strict glycemic control is possible, an absence of
hypoglycemic attacks, a reduced work load in spite
of frequent blood glucose measurements, and a re-
duction in incidents. On the other hand, the de-
merits are high cost, problems associated with an
insufficient quantity of blood obtained for monitor-
ing, the need for much preparation time, and diffi-
culty of operation.
Next-generation artificial endocrine pancreas
It is hoped that development of the next-genera-
tion artificial pancreas will overcome the demerits
of the current models. The development concept
targets treatment where the device can be used in
an operating room or the ICU during an acute
phase. Surgical and emergency applications demand
quick and easy system initiation. Moreover, com-
pact design is essential for operating room and in-
tensive care unit settings which are already crowded
with equipment. The device should also be inexpen-
sive so that this technology can be used for many
patients.
Ideally, the next generation artificial pancreas
should be equipped with a disposable and modular
tubing circuit with an auto-priming function, auto-
matic calibration with quick response in sensor set-
up, and a compact structure. These improvements
are now being developed (Figure 9). It is expected
that such an improved model will be authorized
soon, and we also hope to be able to use it soon.
Prospects
It seems that distinct operative methods for ex-
ample, glycemic control made to order for individ-
ual patients, will become important in the future.
Also, establishment of a simpler and easier to use
perioperative blood glucose control method is ur-
gently needed. We want to make every effort to use
strict intraoperative glycemic control which can lead
to improvement in long-term prognosis for cardio-
vascular surgery patients. In addition, large-scale
multi-center studies in the field of internal medi-
cine such as ACCORD and ADVANCE were re-
ported (51, 52). Lowering of HbA1c from less than
6.5 with the traditional approach to less than 5.8 is
feasible, but development of hypoglycemia is a
problem, making support of at-home management
important. By changing these preoperative care poli-
cies, perioperative glycemic control may benefit in
the future (53).
As for the artificial pancreas, it seems that we
can look forward to a small and light simple low-
cost model with a continuous subcutaneous glucose
sensor using near-infrared light (54). Eventually,
we may see the development of a portable closed-
loop artificial pancreas for at-home management
support.
CONCLUSIONS
In conclusion, strict perioperative glycemic con-
trol is effective for the protection of many organs
and a reduced incidence of infection so that it is
believed that it can lead to improved prognosis for
surgery. It is thought that the main benefit of in-
tensive insulin therapy can be realized in cardiovas-
cular surgery (especially during cardiopulmonary
bypass). However, strict perioperative glycemic con-
trol is difficult due to the need for intermittent blood
glucose measurements and the manual administra-
tion of insulin. Intensive insulin therapy during
cardiovascular surgery may thus be provided by
the use of the artificial pancreas.
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